ATE196847T1 - Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen - Google Patents
Verwendung von mannosephosphaten zur behandlung von fibrotischen störungenInfo
- Publication number
- ATE196847T1 ATE196847T1 AT93906680T AT93906680T ATE196847T1 AT E196847 T1 ATE196847 T1 AT E196847T1 AT 93906680 T AT93906680 T AT 93906680T AT 93906680 T AT93906680 T AT 93906680T AT E196847 T1 ATE196847 T1 AT E196847T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- mannose
- fibrotic disorders
- phosphates
- sec
- Prior art date
Links
- 229910019142 PO4 Inorganic materials 0.000 title abstract 3
- 230000003176 fibrotic effect Effects 0.000 title abstract 2
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
- NDVRKEKNSBMTAX-MVNLRXSJSA-N (2s,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O NDVRKEKNSBMTAX-MVNLRXSJSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000036573 scar formation Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929205800A GB9205800D0 (en) | 1992-03-17 | 1992-03-17 | Treatment of fibrotic disorders |
| PCT/GB1993/000541 WO1993018777A1 (en) | 1992-03-17 | 1993-03-16 | Use of mannose phosphates for the treatment of fibrotic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE196847T1 true ATE196847T1 (de) | 2000-10-15 |
Family
ID=10712310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93906680T ATE196847T1 (de) | 1992-03-17 | 1993-03-16 | Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5520926A (de) |
| EP (1) | EP0728006B1 (de) |
| JP (1) | JP3930556B2 (de) |
| AT (1) | ATE196847T1 (de) |
| AU (1) | AU667887B2 (de) |
| CA (1) | CA2130805C (de) |
| DE (1) | DE69329559T2 (de) |
| DK (1) | DK0728006T3 (de) |
| ES (1) | ES2151903T3 (de) |
| GB (2) | GB9205800D0 (de) |
| GR (1) | GR3035117T3 (de) |
| IL (1) | IL105079A (de) |
| NO (1) | NO306808B1 (de) |
| NZ (1) | NZ249915A (de) |
| PT (1) | PT728006E (de) |
| SG (1) | SG49899A1 (de) |
| WO (1) | WO1993018777A1 (de) |
| ZA (1) | ZA931869B (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
| SE9403137D0 (sv) * | 1994-09-20 | 1994-09-20 | Perstorp Ab | Derivatives of carbohydrates and compositions containing them |
| US6566339B1 (en) | 1995-08-04 | 2003-05-20 | Renovo Limited | Pharmaceutical composition |
| GB9516012D0 (en) * | 1995-08-04 | 1995-10-04 | Univ Manchester | Pharmaceutical composition |
| GB2306481A (en) * | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
| US6093388A (en) * | 1996-08-12 | 2000-07-25 | Btg International Limited | Mannose-6-phosphate composition and its use in treating fibrotic disorders |
| GB9616896D0 (en) * | 1996-08-12 | 1996-09-25 | British Tech Group | Pharmaceutical compositions |
| DE19758059C2 (de) * | 1997-12-29 | 2001-10-04 | Thorsten Marquardt | Verwendung von Mannose zur Bekämpfung der Proteinverlust-Enteropathie |
| WO2002030432A1 (en) * | 2000-06-23 | 2002-04-18 | Cambridgemed, Inc | Agent for reduction of scar formation by using wound alkalinization |
| US20020082222A1 (en) * | 2000-11-30 | 2002-06-27 | Shapira Nathan Andrew | Treatments for neurogenetic disorders, impulse control disorder, and wound healing |
| US20030031689A1 (en) * | 2001-08-09 | 2003-02-13 | Thomas Mammone | Method of skin exfoliation |
| US6822033B2 (en) | 2001-11-19 | 2004-11-23 | United States Gypsum Company | Compositions and methods for treating set gypsum |
| AU2003209308A1 (en) * | 2002-01-22 | 2003-09-02 | Genzyme Corporation | Use of tgf-beta antagonists to treat or to prevent chronic transplant rejection |
| BR0309890A (pt) * | 2002-05-09 | 2005-05-10 | Medigenes | Composição farmacêutica contendo plasma sanguìneo, ou soro sanguìneo utilizada no tratamento de lesões, bem como seu método e processo de aplicação |
| GB0217136D0 (en) | 2002-07-24 | 2002-09-04 | Renovo Ltd | Wound healing & treatment of fibrosis |
| KR100492913B1 (ko) * | 2002-08-23 | 2005-06-03 | 주식회사 태평양 | 피부 감작 및 자극을 완화하는 피부 외용제 조성물 |
| US20050136126A1 (en) * | 2003-03-17 | 2005-06-23 | Cambridgemed, Inc. | Agent for reduction of scar formation by using wound alkalinization |
| JP4634027B2 (ja) * | 2003-05-16 | 2011-02-16 | 花王株式会社 | ビタミンｄ様活性代替用剤 |
| US7276486B2 (en) * | 2004-03-15 | 2007-10-02 | Kimberly-Clark Worldwide, Inc. | Compositions for vaginal treatment |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| JP5481028B2 (ja) * | 2004-10-13 | 2014-04-23 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | ウイルス関連リンパ増殖性障害を処置または予防するための方法 |
| US20070048391A1 (en) * | 2005-08-23 | 2007-03-01 | Cambridgemed, Inc. | Composition for reduction of scar formation on wound scar |
| US7323184B2 (en) * | 2005-08-22 | 2008-01-29 | Healagenics, Inc. | Compositions and methods for the treatment of wounds and the reduction of scar formation |
| EP1948675B1 (de) | 2005-10-25 | 2014-07-30 | The Johns Hopkins University | Verfahren und zusammensetzungen zur behandlung von marfan-syndrom und verwandten erkrankungen |
| US8454952B2 (en) | 2006-03-13 | 2013-06-04 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
| DK2083863T3 (da) | 2006-10-03 | 2015-06-22 | Genzyme Corp | Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi |
| US8070895B2 (en) | 2007-02-12 | 2011-12-06 | United States Gypsum Company | Water resistant cementitious article and method for preparing same |
| US8329308B2 (en) | 2009-03-31 | 2012-12-11 | United States Gypsum Company | Cementitious article and method for preparing the same |
| GB0910078D0 (en) | 2009-06-11 | 2009-07-22 | Renovo Ltd | Uses of mannose-6-phosphate |
| GB0916333D0 (en) | 2009-09-17 | 2009-10-28 | Renovo Ltd | Improvement of tendon repair |
| GB0916334D0 (en) * | 2009-09-17 | 2009-10-28 | Renovo Ltd | Inhibition of tendon adhesions |
| ME02464B (de) | 2010-03-12 | 2017-02-20 | Genzyme Corp | Kombinationstherapie zur Behandlung von Brustkrebs |
| WO2012087434A2 (en) * | 2010-11-05 | 2012-06-28 | Healthypharma, Llc | Use of phosphoric acid |
| CA2823154A1 (en) | 2010-12-27 | 2012-07-05 | Lsip, Llc | Ips cells and method for generating same |
| US20140308275A1 (en) | 2011-07-27 | 2014-10-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Methods for diagnosing and treating myhre syndrome |
| WO2013062544A1 (en) | 2011-10-26 | 2013-05-02 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
| EP2799537B1 (de) | 2011-12-28 | 2021-09-22 | Kyoto Prefectural Public University Corporation | Normalisierung der züchtung von hornhautendothelzellen |
| CA2927898C (en) | 2013-10-31 | 2021-11-16 | Kyoto Prefectural Public University Corporation | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
| US10882903B2 (en) | 2015-05-18 | 2021-01-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
| EP4490353A4 (de) * | 2022-03-08 | 2026-01-14 | Univ Of Mississippi Medical Center | Artikel und verfahren für verbesserte gewebeheilung |
| CN115260256A (zh) * | 2022-07-22 | 2022-11-01 | 河南中医药大学 | 一种甘露糖磷酸化衍生物及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE756953A (fr) * | 1969-10-02 | 1971-04-01 | Merck & Co Inc | Potentialisation d'antibiotiques |
| JPS5631156B2 (de) * | 1973-09-25 | 1981-07-20 | ||
| IT1170618B (it) * | 1981-01-13 | 1987-06-03 | Foscama Biomed Chim Farma | Preparato farmacologico di frutto sio-1,6-difosfato ad azione terapeutica nei pazienti ustionati |
| US4703040A (en) * | 1985-04-03 | 1987-10-27 | Markov Angel K | Treatment of adult respiratory distress syndrome (ARDS) using fructose diphosphate (FDP) |
| ATE78166T1 (de) * | 1985-10-22 | 1992-08-15 | Silvetti Anthony N | Monosaccharide enthaltende zusammensetzung zum heilen von wunden. |
| US4889844A (en) * | 1985-10-22 | 1989-12-26 | Silvetti Sr Anthony N | Fructose containing wound healing preparation |
| AU607690B2 (en) * | 1985-12-24 | 1991-03-14 | Marion Laboratories, Inc. | Use of synthetic sulfated saccharides to enhance wound healing |
| JPS62243675A (ja) * | 1986-04-15 | 1987-10-24 | Kao Corp | ｐＨ緩衝法 |
| ATE139699T1 (de) * | 1988-08-19 | 1996-07-15 | Univ Australian | Auf phosphozucker basierende antientzündliche und/oder immunitätsunterdrückende arzneimittel |
| GB8917414D0 (en) * | 1989-07-29 | 1989-09-13 | Translift Material Handling | Narrow aisle lift truck |
| WO1991004748A1 (en) * | 1989-09-29 | 1991-04-18 | La Jolla Cancer Research Foundation | INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX |
| SE8904354D0 (sv) * | 1989-12-21 | 1989-12-21 | Matti Siren | A pharmaceutical composition |
| GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
| JPH0558868A (ja) * | 1991-08-27 | 1993-03-09 | Kao Corp | 親水性紫外線吸収剤及びこれを含有する化粧料 |
| WO1993019783A1 (en) * | 1992-04-01 | 1993-10-14 | The Whittier Institute For Diabetes And Endocrinology | Methods of inhibiting or enhancing scar formation in the cns |
| JPH09155319A (ja) * | 1995-12-13 | 1997-06-17 | Takeo Tsutsui | 重金属含有焼却灰等、シュレッダーダストの無公害化処理方法および再利用材の製造方法 |
-
1992
- 1992-03-17 GB GB929205800A patent/GB9205800D0/en active Pending
-
1993
- 1993-03-16 EP EP93906680A patent/EP0728006B1/de not_active Expired - Lifetime
- 1993-03-16 GB GB9305344A patent/GB2265310B/en not_active Expired - Lifetime
- 1993-03-16 AT AT93906680T patent/ATE196847T1/de active
- 1993-03-16 SG SG1996008660A patent/SG49899A1/en unknown
- 1993-03-16 CA CA002130805A patent/CA2130805C/en not_active Expired - Lifetime
- 1993-03-16 DE DE69329559T patent/DE69329559T2/de not_active Expired - Lifetime
- 1993-03-16 WO PCT/GB1993/000541 patent/WO1993018777A1/en not_active Ceased
- 1993-03-16 US US08/290,939 patent/US5520926A/en not_active Expired - Lifetime
- 1993-03-16 DK DK93906680T patent/DK0728006T3/da active
- 1993-03-16 PT PT93906680T patent/PT728006E/pt unknown
- 1993-03-16 JP JP51635793A patent/JP3930556B2/ja not_active Expired - Lifetime
- 1993-03-16 ZA ZA931869A patent/ZA931869B/xx unknown
- 1993-03-16 ES ES93906680T patent/ES2151903T3/es not_active Expired - Lifetime
- 1993-03-16 NZ NZ249915A patent/NZ249915A/en not_active IP Right Cessation
- 1993-03-16 IL IL105079A patent/IL105079A/en not_active IP Right Cessation
- 1993-03-16 AU AU37590/93A patent/AU667887B2/en not_active Expired
-
1994
- 1994-09-16 NO NO943451A patent/NO306808B1/no not_active IP Right Cessation
-
2000
- 2000-12-19 GR GR20000402805T patent/GR3035117T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT728006E (pt) | 2001-04-30 |
| SG49899A1 (en) | 1998-06-15 |
| DE69329559D1 (de) | 2000-11-16 |
| ES2151903T3 (es) | 2001-01-16 |
| GB9205800D0 (en) | 1992-04-29 |
| IL105079A (en) | 1998-06-15 |
| IL105079A0 (en) | 1993-07-08 |
| GB9305344D0 (en) | 1993-05-05 |
| NO943451D0 (no) | 1994-09-16 |
| AU667887B2 (en) | 1996-04-18 |
| NO943451L (no) | 1994-09-16 |
| AU3759093A (en) | 1993-10-21 |
| GR3035117T3 (en) | 2001-03-30 |
| NO306808B1 (no) | 1999-12-27 |
| CA2130805C (en) | 2003-06-24 |
| CA2130805A1 (en) | 1993-09-30 |
| EP0728006B1 (de) | 2000-10-11 |
| EP0728006A1 (de) | 1996-08-28 |
| ZA931869B (en) | 1994-09-16 |
| WO1993018777A1 (en) | 1993-09-30 |
| NZ249915A (en) | 1996-08-27 |
| JPH07504909A (ja) | 1995-06-01 |
| GB2265310B (en) | 1996-09-25 |
| DE69329559T2 (de) | 2001-05-31 |
| DK0728006T3 (da) | 2000-10-30 |
| US5520926A (en) | 1996-05-28 |
| JP3930556B2 (ja) | 2007-06-13 |
| GB2265310A (en) | 1993-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE196847T1 (de) | Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen | |
| ATE164067T1 (de) | Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen | |
| DE69733132D1 (de) | Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen | |
| RU94031102A (ru) | Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний | |
| DE69526937D1 (de) | Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen | |
| ATE207356T1 (de) | Verwendung von tiagabin zur behandlung von schlafstörungen | |
| DE69403969D1 (de) | Levobupivacain nützlich zur behandlung von chronischen schmerzen | |
| ATE198830T1 (de) | Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems | |
| DE69532804D1 (de) | Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis | |
| ATE321548T1 (de) | Verwendung von statin zur behandlung von hauterkrankungen | |
| ATE258796T1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| ATE214272T1 (de) | Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz | |
| ATE251631T1 (de) | Dipohosphonsäuresalze für die behandlung von osteoporose | |
| DE59902666D1 (de) | Edelfosin zur behandlung von hirntumoren | |
| ATE234614T1 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren | |
| DE69818809D1 (de) | Verfahren zur behandlung von narbengewebe | |
| ATE275964T1 (de) | Verwendung von betalycan zur verminderung der narbenbildung | |
| ATE236633T1 (de) | Topische verwendung von loperamid zur behandlung mikrobieller infektionen | |
| DE69124382D1 (de) | Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände | |
| DE59410340D1 (de) | Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen | |
| DE3865283D1 (de) | Butylhydroxyanisole zur behandlung von retrovirus-krankheiten. | |
| ATE288263T1 (de) | Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis) | |
| DE69732851D1 (de) | Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren | |
| DE69832796D1 (de) | Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen | |
| ATE150645T1 (de) | Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |